The insulin-like growth factor system and its receptors: A potential novel anticancer target

Biologics: Targets and Therapy

Volumn 2, Issue 4, 2008, Pages 855-864

  Lindsay, Colin R ^a   Jeffry Evans, T R ^a,b  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Clinical trials; Growth factor; IGF 1; Insulin

Indexed keywords

EID: 79956273577     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s3841     Document Type: Review

References (92)

1. Attard G, Fong PC, Molife R, et al. 2006. Phase I trial involving the pharmacodynamic (PD) study of circulating tumor cells, of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), with docetaxel (D) in patients with advanced cancer. ASCO Annual Meeting Proceedings part I [abstract]. J Clin Oncol, 24(18S):3023.
2. Baxter RC. 2000. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Physiol Endocrinol Metab, 278:E967-E976.
3. Bernstein L, Patel AV, Ursin G, et al. 2005. Lifetime recreational exercise activity and breast cancer risk among black women and white women. J Natl Cancer Institute, 97:1671-9.
4. Bohula EA, Salisbury AJ, Sohail M, et al. 2003. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem, 278:15991-7.
5. Boyd NF, Stone J, Martin LJ, et al. 2002. The association of breast mitogens with mammographic densities. Br J Cancer, 87:876-82.
6. Burtrum D, Zhu Z, Lu D, et al. 2003. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res, 63:8912-21.
7. Chan JM, Stampfer MJ, Ma J, et al. 2001. Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. Am J Clin Nutr, 74:549-54.
8. Chernicky CL, Yi L, Tan H, et al. 2000. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther, 7:384-95.
9. Cohen BD, Baker DA, Soderstrom C, et al. 2005. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res, 11:2063-73.
10. Collett-Solberg PF, Cohen P. 1996. The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am, 25:591-614.
11. De Bono JS, Attard G, Adjei A, et al. 2007. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res, 13:3611-6.
12. DeChiara TM, Robertson EJ, Efstratiadis A. 1991. Parental imprinting of the mouse insulin-like growth factor II gene. Cell, 64:849-59.
13. DiGiovanni J, Kiguchi K, Frijhoff A, et al. 2000. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci U S A, 97:3455-60.
14. Dufourny B, Alblas J, van Teeffelen HA, et al. 1997. Mitogenic signalling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem, 272:31163-71.
15. Dunn SE, Kari FW, French J, et al. 1997. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res, 57:4667-72.
16. Dunn SE, Ehrlich M, Sharp NJ, et al. 1998. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res, 58:3353-61.
17. El Atiq F, Garrouste F, Remacle-Bonnet M, et al. 1994. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer, 57:491-7.
18. Engeland A, Tretli S, Bjorge T. 2003. Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br J Cancer, 89:1237-42.
19. Favoni RE, de Cupis A, Perrotta A, et al. 1995. Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early-and late-stage breast cancer: mutual relationship and possible correlations with patients' hormonal status. J Cancer Res Clin Oncol, 121:674-82.
20. Federici M, Porzio O, Zucaro L, et al. 1997. Distribution of insulin/insulin-like growth factor-1 hybrid receptors in human tissues. Mol Cell Endocrinol, 129:121-6.
21. Firth SM, Baxter RC. 2002. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev, 23:824-54.
22. Freudenheim JL, Marshall JR, Vena JE, et al. 1996. Premenopausal breast cancer risk and intake of vegetables, fruits, and related nutrients. J Natl Cancer Institute, 88:340-8.
23. Furlanetto RW, Harwell SE, Frick K. 1994. Insulin-like growth factor I induces cyclin D1 expression MG63 human osteosarcoma cells in vitro. Mol Endocrinol, 8:510-7.
24. Garcia-Echeverria C, Pearson MA, Marti A, et al. 2004. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell, 5:231-9.
25. Giovanucci E, Pollak M, Liu Y, et al. 2003. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev, 12:84-9.
26. Guerra FK, Eijan AM, Puricelli L, et al. 1996. Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. Int J Cancer, 65:812-20.
27. Guler HP, Zapf J, Froesch ER. 1987. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med, 317:137-40.
28. Haluska P, Carboni JM, Loegering DA, et al. 2006. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res, 66:362-71.
29. Haluska P, Shaw HM, Batzel GN, et al. 2007. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res, 13:5834-40.
30. Hankinson L, Strohm O, Osterziel K, et al. 1998. Insulin-like growth factor-I and risk of breast cancer. Lancet, 352:489-99.
31. Herbst RS, Giaccone G, Schiller JH, et al. 2004. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol, 22:785-94.
32. Higano CS, Yu EY, Whiting MS, et al. 2007. A Phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors [abstract]. ASCO Prostate Cancer Symposium, 269.
33. Holmes MD, Chen WY, Feskanich D, et al. 2005. Physical activity and survival after breast cancer diagnosis. JAMA, 293:2479-86.
34. Jarrard DF, Bussemakers MJ, Bova GS, et al. 1995. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin Cancer Res, 1:1471-8.
35. Ji QS, Mulvihil MJ, Rosenfeld-Franklin M, et al. 2007. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther, 6:2158-67.
36. Jones JI, Clemmons DR. 1995. Insulin-like growth factora and their binding proteins: iological actions. Endocr Rev, 16:3-34.
37. Karp DD, Paz-Ares LG, Blakely LJ, et al. 2007. Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751,871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings part I [abstract]. J Clin Oncol, 25(18S):7506.
38. Kelley KM, Oh Y, Gargosky SE, et al. 1996. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol, 28:619-37.
39. Khandwala HM, McCutcheon IE, Flyvbjerg A, et al. 2000. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev, 21:215-44.
40. Lacy M, Alsina M, Melvin CL, et al. 2006. Phase I first-in-human dose escalation study of CP-751,871, a specific monoclonal antibody against the insulin like growth factor 1 receptor. ASCO Annual Meeting Proceedings part I [abstract]. J Clin Oncol, 24(18S):7609.
41. Landin-Wilhelmsen K, Wilhelmsen L, Lapps G, et al. 1994. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol, 41:351-7.
42. Lawlor DA, Okasha M, Gunnell D, et al. 2003. Associations of adult measures of childhood growth with breast cancer: findings from the British Women's Heart and Health Study. Br J Cancer, 89:81-7.
43. LeRoith D, Werner H, Beitner-Johnson D, et al. 1995. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev, 16:143-63.
44. LeRoith D, Roberts Jr. CT. 2003. The insulin-like growth factor system and cancer. Cancer Lett, 195:127-37.
45. Letsch M, Schally AV, Busto R, et al. 2003. Growth hormonereleasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and-independent prostate cancers. Proc Natl Acad Sci U S A, 100:1250-5.
46. Li SL, Liang SJ, Guo N, et al. 2000. Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth. Cancer Immunol Immunother, 49:243-52.
47. Liu JP, Baker J, Perkins AS, et al. 1993. Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGFI) and type I IGF receptor (IGFIr). Cell, 75:59-72.
48. Lu S, Archer MC. 2003. Insulin-like growth factor binding protein-1 over-expression in transgenic mice inhibits hepatic preneoplasia. Mol Carcinogen, 36:142-6.
49. Ma J, Pollak M, Giovannucci E, et al. 1999. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst, 91:628-9.
50. Macdonald RG, Pfeffer SR, Coussens L, et al. 1988. A single receptor binds both insulin-like growth factor II and mannose-6-phosphate. Science, 239:1134-7.
51. Majeed N, Kaplan P, Blouin M, et al. 2003. Lit is the first germ-line mutation to reduce prostate cancer risk and prolong survival in the TRAMP transgenic model. Proc Am Assoc Cancer Res, 44:877.
52. Maloney EK, McLaughlin JL, Dagdigian NE, et al. 2003. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res, 63:5073-83.
53. Maskarinec G, William AE, Kaaks R. 2003. A cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer, 107:996.
54. Meyer GE, Shelden E, Kim B, et al. 2001. Insulin-like growth factor I stimulates motility in human neuroblastoma cells. Oncogene, 20:7542-50.
55. Michels KB, Xue F, Terry KL, et al. 2006. Longitudinal study of birthweight and the incidence of breast cancer in adulthood. Carcinogenesis, 27:2464-8.
56. Minshall C. Arkins S, Straza J, et al. 1997. IL-4 and insulin-like growth factor I inhibit the decline in Bcl-2 and promote the survival of IL-3 deprived myeloid progenitors. J Immunol, 159:1225-32.
57. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. 2004. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell, 5:221-30.
58. Morgillo F, Kim WY, Kim ES, et al. 2007. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res, 13:2795-803.
59. Moses AC, Young SC, Morrow LA, et al. 1996. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes, 45:91-100.
60. Nahta R, Yuan LX, Zhang B, et al. 2005. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res, 65:11118-28.
61. Oates AJ, Schumaker LM, Jenkins SB, et al. 1998. The mannose 6-phosphate/ insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat, 47:269-81.
62. Oda H, Shimizu S, Minami K, et al. 1997. Loss of imprinting of the IGF2 gene in a Wilms' tumor in an adult. J Natl Cancer Institute, 89:1813-4.
63. Oh JS, Kucab JE, Bushel PR, et al. 2002. Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia, 4:204-17.
64. Palmqvist R, Hallmans G, Rinaldi S, et al. 2002. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut, 50:642-6.
65. Parrizas M, LeRoith D. 1997. Insulin-like growth factor I inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology, 138:1355-8. Patel BB, Sengupta R, Qazi S, et al. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer, 122:267-73.
66. Peyrat JP, Bonneterre J, Hecquet B, et al. 1993. Plasma insulin-like growth factor-I (IGFI) concentrations in himan breast cancer. Eur J Cancer, 29A:492-7.
67. Pollak M. 2001. Insulin-like growth factors and prostate cancer. Epidemiol Rev, 23:59-66.
68. Pollak MN, Schally AV. 1998. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Med Biol, 217:143-52.
69. Pollak MN, Schernhammer ES, Hankinson SE. 2004. Insulin-like growth factors and neoplasia. Nat Rev Cancer, 4:505-18.
70. Reeves GK, Pirie K, Beral V, et al. 2007. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ, 335:1134.
71. Reinmuth N, Liu W, Fan F, et al. 2002. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res, 8:3259-69.
72. Rogler CE, Yang D, Rossetti L, et al. 1994. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem, 269:13779-84.
73. Rowinsky EK, Youssoufian H, Tonra JR, et al. 2007. IMC-A12, a human IgG1 monoclonal antibod to the insulin-like growth factor I receptor. Clin Cancer Res, 13(18 Pt 2):5549s-5555s.
74. Rudman D, Mattson DE. 1994. Serum insulin-like growth factor I in healthy older men in relation to physical activity. J Am Geriatr Soc, 42:71-6.
75. Sachdev D, Li SL, Hartell JS, et al. 2003. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res, 63:627-35.
76. Sandhu MS, Luben R, Day NE, et al. 2002. Self-reported birth weight and subsequent risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev, 11:935-8.
77. Satyamoorthy K, Li G, Vaidya B, et al. 2002. Insulin-like growth factor-I-induced migration of melanoma cells is mediated by interleukin-8 induction. Cell Growth Differ, 13:87-93.
78. Schmitz F, Hartmann H, Stumpel F, et al. 1991. In vivo metabolic action of insulin-like growth factor I in adult rats. Diabetologia, 34:144-9.
79. Scotlandi K, Avnet S, Benini S, et al. 2002. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer, 101:11-6.
80. Sell C, Dumenil G, Deveaud C, et al. 1994. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol, 14:3604-12.
81. Slamon DJ, Leyland-Jones B, Shak S, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344:783-92.
82. Stattin P, Rinaldi S, Biessy C, et al. 2004. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based non-screened cohort. J Clin Oncol, 22:3104-12.
83. Tennant MK, Thrasher JB, Twomey PA, et al. 1996. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab, 81:3774-82.
84. Tibblin G, Eriksson M, Cnattingius S, et al. 1995. High birthweight as a predictor of prostate cancer risk. Epidemiology, 6:423-4.
85. Tornell J, Rymo L, Isakkson OG. 1991. Induction of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice. Int J Cancer, 49:114-7.
86. Vadgama JV, Wu Y, Datta G, et al. 1999. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology, 57:330-40.
87. Wu KD, Zhou L, Burtrum D, et al. 2007. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother, 56:343-57.
88. Wu Y, Cui K, Miyoshi K, et al. 2003. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res, 63:4384-8. Xia Y, Jin L, Zhang B, et al. The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells. Life Sci, 80:2161-9.
89. Xie Y, Skytting B, Nilsson G, et al. 1999. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res, 59:3588-91.
90. Yee D. 2006. Targeting insulin-like growth factor pathways. Br J Cancer, 94:465-8.
91. Yu H, Rohan T. 2000. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92:1472-89.
92. Zhang L, Zhou W, Velculescu VE, et al. 1997. Gene expression profiles in normal and cancer cells. Science, 276:1268-72.